# Test Results: statistics/interpretation-brainstorming.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-25.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** statistics/interpretation-brainstorming.md
- **Model:** claude-sonnet-4.6
- **Model ID (pinned):** claude-sonnet-4-6
- **Endpoint:** native
- **Date:** 2026-06-25
- **Tester:** cross-model-harness
- **Assembly strategy:** test-only
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
````
Context: I have completed an experiment and am interpreting the results. I want to think through possible interpretations thoroughly.

Research question: Does fecal microbiota transplantation from lean donors improve metabolic outcomes in obese mice?

Experimental design (brief):
- 3 groups (n=10 each): Control (PBS), FMT from lean donors, FMT from obese donors
- High-fat diet-induced obese mice, 8 weeks treatment
- Measured: body weight, fasting glucose, microbiome composition

Results summary:
- Main finding: FMT-lean group had significantly lower fasting glucose than Control (p=0.01) and FMT-obese (p=0.03)
- Effect size: Mean glucose 145 vs 180 mg/dL (FMT-lean vs Control)
- Body weight: No significant differences between any groups
- Microbiome: FMT-lean group showed higher diversity and different community composition
- The donor-derived taxa were detectable in recipients
- Unexpected: FMT-obese group showed slightly (non-significant) lower glucose than Control

My initial interpretation: Lean-donor microbiota transfers metabolically beneficial effects to obese recipients, potentially through specific bacterial taxa that improve glucose regulation.

Task: Help me think through these results critically:

1. **Support for initial interpretation**: What evidence supports my interpretation? How strong is it?

2. **Alternative interpretations**: What other explanations could produce these results? For each alternative:
   - What would it predict?
   - How could I distinguish it from my interpretation?

3. **Potential confounds**: What factors might have influenced the results that aren't captured in my interpretation?

4. **Limitations to acknowledge**: What caveats should I include when presenting these findings?

5. **Questions for follow-up**: What additional experiments or analyses would strengthen the interpretation?

6. **What the results don't show**: What conclusions would be overreach?

Constraints:
- Be genuinely critical—I want to anticipate reviewer objections
- Don't just agree with my interpretation; actively generate alternatives
- Distinguish between plausible alternatives and unlikely ones
- Focus on scientific interpretation, not just statistical significance
````

## Model Output
````
# Critical Analysis of FMT Metabolic Outcomes Experiment

---

## 1. Support for Your Initial Interpretation

### What the evidence actually establishes

**Strongest support:**
- The glucose difference is statistically significant with a meaningful effect size (~19% reduction, 35 mg/dL). This isn't a marginal finding.
- Donor-derived taxa are detectable in recipients — this is a necessary (though not sufficient) condition for your mechanism. Without engraftment, the interpretation would collapse entirely.
- The microbiome composition difference aligns directionally with the metabolic difference, providing biological plausibility.
- The FMT-obese control behaves differently from FMT-lean, suggesting the effect is donor-specific rather than an artifact of the FMT procedure itself.

**How strong is it overall?**

Moderate, but not yet compelling for mechanism. You have established an *association* between lean-donor FMT and improved glucose regulation, with evidence of engraftment. What you have not established is the *causal pathway*. The evidence is consistent with your interpretation but does not yet distinguish it from several alternatives below. A reviewer would likely say: "Interesting association, but the mechanism is unresolved and the effect is incomplete (glucose without weight change)."

---

## 2. Alternative Interpretations

### Alternative A: Non-specific procedural effects (stress/immune stimulation)
**Argument:** The FMT procedure itself — gavage, handling, introduction of foreign biological material — could trigger immune or neuroendocrine responses that transiently affect glucose metabolism, independent of specific microbial content.

**What it predicts:**
- FMT-obese group should also show some glucose improvement relative to control (which you actually observe — the non-significant trend)
- Effect might diminish over time as the novelty stimulus fades
- The effect would be reproducible with heat-killed bacteria or filtered supernatant

**How to distinguish it:**
- Heat-killed donor microbiota control would be the cleanest test
- Time-course data: does the glucose difference persist, grow, or fade?
- Your FMT-obese trend is actually *mild evidence for this alternative* — take it seriously

**Plausibility: Moderate.** The FMT-obese trend is the key observation here. You should address this directly rather than dismissing it as non-significant noise.

---

### Alternative B: Dietary/caloric intake differences
**Argument:** Microbiome composition affects food palatability, appetite signaling (GLP-1, PYY, ghrelin), and eating behavior. FMT-lean mice might simply be eating less or absorbing fewer calories, producing lower glucose without any direct metabolic reprogramming.

**What it predicts:**
- Caloric intake should differ between groups
- Body weight *should* eventually diverge if this were sustained (the absence of weight difference is a partial argument against this, but 8 weeks may be insufficient, or the effect may be too small)
- Cecal/fecal energy content might differ

**How to distinguish it:**
- Pair-feeding experiment: restrict control mice to the same caloric intake as FMT-lean mice
- Measure food intake directly (you may not have done this — if not, this is a significant gap)
- Measure gut hormones (GLP-1, PYY)

**Plausibility: Moderate-high.** The absence of weight difference doesn't rule this out — glucose can change before weight does, and the effect size may be too small to detect weight differences with n=10.

---

### Alternative C: Bile acid profile alteration
**Argument:** Gut bacteria extensively modify bile acids, which are potent signaling molecules that directly regulate glucose metabolism via FXR and TGR5 receptors, independent of any "metabolically beneficial taxa" narrative.

**What it predicts:**
- Fecal and serum bile acid profiles should differ between groups
- The effect could be mediated by a small number of bile acid-modifying taxa (e.g., BSH-expressing bacteria) rather than overall community composition
- Germ-free mouse experiments with specific taxa would recapitulate the effect

**How to distinguish it:**
- Bile acid profiling (targeted metabolomics)
- FXR/TGR5 pathway markers in liver and intestinal tissue
- This is actually *compatible* with your interpretation but reframes the mechanism more specifically

**Plausibility: High.** This is one of the best-characterized microbiome-metabolism links and should probably be in your mechanistic discussion regardless.

---

### Alternative D: Short-chain fatty acid (SCFA) mediation
**Argument:** Higher diversity microbiomes (as you observed) often produce more diverse and abundant SCFAs, which improve insulin sensitivity through GPR41/43 signaling and histone deacetylase inhibition.

**What it predicts:**
- Fecal SCFA profiles (acetate, propionate, butyrate) should differ
- Colonic epithelial gene expression related to SCFA signaling should differ
- The effect might be reproducible by SCFA supplementation alone

**How to distinguish it:**
- Fecal SCFA quantification (relatively straightforward)
- This is also compatible with your interpretation but again specifies mechanism

**Plausibility: High.** This is a well-supported pathway and a natural follow-up analysis if you have stored samples.

---

### Alternative E: Diversity itself is the active variable, not specific taxa
**Argument:** Your interpretation emphasizes "specific bacterial taxa," but the observed higher diversity in FMT-lean recipients might be the relevant variable — more diverse communities may provide more metabolic redundancy and resilience, regardless of which specific taxa are present.

**What it predicts:**
- The correlation between diversity metrics and glucose should be stronger than the correlation between any specific taxon and glucose
- Diversity-matched FMT from obese donors might produce similar effects
- The specific taxa that engrafted may vary across individual mice while the glucose effect is consistent

**How to distinguish it:**
- Correlate individual diversity metrics (Shannon, Faith's PD) with individual glucose values within groups
- Look at whether the glucose effect is consistent across mice or driven by a subset with high engraftment of specific taxa

**Plausibility: Moderate.** This is a genuine scientific debate in the field. Your current data cannot distinguish "specific taxa" from "diversity effect."

---

### Alternative F: Donor batch effects / donor-specific factors unrelated to leanness
**Argument:** Your lean donors may have had some characteristic *other than* leanness that drove the effect — age, stress level, housing conditions, specific pathogen exposure history, or even a transient infection. The "lean" label may be correlational with the true active variable.

**What it predicts:**
- Replication with different lean donors might show variable results
- The effect might not replicate in a different facility or mouse strain

**How to distinguish it:**
- Multiple independent donor cohorts (this is a major limitation if you used a single donor pool)
- Characterize donors beyond body weight: glucose tolerance, microbiome composition, inflammatory markers

**Plausibility: Moderate-high, and often underappreciated.** Single-donor-pool experiments are a known vulnerability in FMT research. Reviewers will ask how many donors you used.

---

## 3. Potential Confounds

### Confounds you should actively investigate

| Confound | Why it matters | How to assess |
|---|---|---|
| **Cage effects** | Coprophagy means mice in the same cage share microbiomes; if FMT groups were housed together, this is a major confound | Report housing arrangement; ideally mice were individually housed or cages were randomized |
| **Antibiotic pre-treatment protocol** | If you used antibiotics to clear the native microbiome before FMT, the antibiotic regimen itself affects metabolism and the gut environment | Ensure antibiotic protocol was identical across groups; include antibiotic-only control |
| **FMT preparation variability** | Batch-to-batch variation in FMT preparation (freeze-thaw cycles, anaerobic handling, concentration) could introduce noise | Standardize and document preparation; ideally use a single prepared batch |
| **Baseline differences** | Were groups truly equivalent at baseline before FMT? | Report baseline glucose and weight; confirm randomization was effective |
| **Stress from gavage** | Repeated gavage is stressful; stress hormones (corticosterone) directly affect glucose | Measure corticosterone or use less invasive delivery method |
| **Incomplete engraftment variability** | Individual mice may have had highly variable engraftment; averaging across the group may obscure this | Correlate engraftment level (donor taxa abundance) with glucose in individual mice |

---

## 4. Limitations to Acknowledge

### Tier 1: Must acknowledge (fatal if ignored by reviewers)

- **Mechanism is unresolved.** You have demonstrated an association and engraftment, but the causal pathway from microbiome change to glucose improvement is not established. The "specific taxa" claim in your interpretation is not yet supported.
- **No weight effect.** This is genuinely puzzling and requires discussion, not dismissal. Glucose improvement without weight change could mean: (a) the effect is real but upstream of weight change, (b) the effect is on insulin sensitivity rather than adiposity, or (c) the effect is smaller than it appears and weight would eventually diverge. Each has different implications.
- **Short duration.** Eight weeks is sufficient to see glucose changes but may not reflect long-term stability of engraftment or metabolic effects.
- **Mouse-to-human translation.** High-fat diet mouse models have a poor track record of translating to human metabolic disease. This is standard but necessary.

### Tier 2: Should acknowledge

- **Sample size.** n=10 per group is reasonable for a pilot study but underpowered for subgroup analyses or correlation analyses within groups.
- **Single sex assumption.** If you used only male mice (common in metabolic studies), sex-specific microbiome-metabolism interactions are unaddressed.
- **Fasting glucose only.** This is a limited metabolic readout. Glucose tolerance tests (GTT), insulin tolerance tests (ITT), and HOMA-IR would substantially strengthen the metabolic phenotyping.
- **Donor pool size.** If you pooled from few donors, donor-specific effects cannot be separated from lean-donor effects.

### Tier 3: Contextual caveats

- The FMT-obese non-significant trend deserves honest discussion — it either supports a non-specific effect or suggests obese-donor microbiota has some modest beneficial component, neither of which fits cleanly into your narrative.

---

## 5. Questions for Follow-Up

### Immediate (can be done with existing samples)

1. **SCFA quantification from stored fecal samples** — directly tests Alternative D and is relatively inexpensive
2. **Correlation analyses within groups** — correlate Shannon diversity, specific taxon abundance, and engraftment level with individual mouse glucose values; this tests whether the effect is driven by specific taxa or diversity
3. **Bile acid profiling** if serum/fecal samples were stored — tests Alternative C
4. **Re-examine food intake data** if measured — tests Alternative B

### Short-term follow-up experiments

5. **Glucose tolerance test (GTT) and insulin tolerance test (ITT)** — distinguishes insulin resistance from impaired insulin secretion; essential for mechanistic interpretation
6. **Germ-free mouse colonization with specific taxa** — the gold standard for establishing causality; identify candidate taxa from your 16S data and test them individually or in defined consortia
7. **Multiple independent donor cohorts** — critical for ruling out Alternative F; use donors from different sources or time points
8. **Extended time course** — does the glucose effect persist at 16 weeks? Does weight eventually diverge?

### Longer-term mechanistic experiments

9. **Antibiotic ablation of engrafted microbiome** — if you re-treat FMT-lean mice with antibiotics and glucose returns to baseline, this strongly supports microbiome causality
10. **Fecal metabolomics** — untargeted approach to identify metabolic intermediates that differ between groups, which can then guide mechanistic hypotheses

---

## 6. What the Results Don't Show

### Overreach to avoid — stated explicitly

> ❌ "Lean-donor FMT reverses obesity-associated metabolic dysfunction"
> 
> *Why:* Body weight was unchanged. "Metabolic dysfunction" is broader than fasting glucose alone.

> ❌ "Specific bacterial taxa mediate the glucose-lowering effect"
> 
> *Why:* You have identified taxa that differ between groups, but you have not established that any specific taxon is causally responsible. Correlation between taxon presence and glucose is not causation.

> ❌ "FMT from lean donors improves insulin sensitivity"
> 
> *Why:* You measured fasting glucose, not insulin sensitivity. These are related but distinct. You need ITT/GTT/HOMA-IR to make this claim.

> ❌ "These findings suggest FMT could be a therapeutic strategy for human obesity"
> 
> *Why:* Mouse-to-human translation for metabolic disease is notoriously poor. This is a hypothesis-generating finding, not a translational one.

> ❌ "Obese-donor microbiota has no metabolic effect"
> 
> *Why:* The non-significant trend in FMT-obese suggests there may be an effect; your study is underpowered to confirm or rule it out.

### What you *can* reasonably claim

> ✅ "Lean-donor FMT was associated with significantly lower fasting glucose in diet-induced obese mice, accompanied by increased microbiome diversity and engraftment of donor-derived taxa"

> ✅ "These results are consistent with the hypothesis that lean-donor microbiota contributes to improved glucose regulation, though the mechanism remains to be established"

> ✅ "The divergent metabolic outcomes between FMT-lean and FMT-obese recipients suggest that donor metabolic phenotype influences the metabolic effects of FMT"

---

## Summary: The Core Tension in Your Data

The most intellectually honest framing of your results is this: **you have a clean, significant glucose effect with good biological plausibility, but two observations complicate a simple narrative** — the absence of weight change and the non-significant FMT-obese trend. A strong paper will engage with both directly rather than treating them as noise. The weight dissociation in particular is worth framing as a finding rather than a limitation: glucose regulation and adiposity may be separable targets of microbiome intervention, which is itself an interesting result.
````

## Assessment

_Machine-suggested (UNCONFIRMED) — drafted by Claude Opus 4.7 on 2026-06-26 to speed T4 review. An author must independently read the Model Output above and set the real Recommendation. Anything labeled here is triage, not domain expert review._

**Machine triage:** Output covers all required dimensions. Complete, no truncation. Concludes with explicit "Core Tension" framing — useful for manuscript discussion. Argues weight dissociation should be framed as a finding rather than limitation. Strong cross-model agreement on substantive issues.

**Suggested verdict (UNCONFIRMED):** Pass

**What still needs human verification:**
- Whether "weight-glucose dissociation as finding" framing aligns with reviewer expectation
- That the recommended manuscript-level framing is appropriate
- Spot-check the analysis of FMT-obese non-significance

## Overall Assessment
- **Recommendation:** Pass
- **Notes:** Alex Alexiev (2026-06-29): **What still needs human verification:**
- Whether "weight-glucose dissociation as finding" framing aligns with reviewer expectation: I think so but also there are other research studies that have shown this result as well
- That the recommended manuscript-level framing is appropriate: yes
- Spot-check the analysis of FMT-obese non-significance: yes

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
